The human gut microbiome (GM) in healthy people is chronically exposed to tetracycline (TET) via environmental exposure and dietary uptake. However, limited information is available on its effect on the GM metabolome and effect on the host, especially at the dietary exposure level. Here, we investigated how TET at both sub-pharmaceutical and dietary exposure levels affects the metabolome and the secretome-induced host immune response by studying several representative gut bacteria. Interestingly, the metabolome showed a highly speciesspecific pattern with a distinct dose-response relationship. B. fragilis was highly sensitive to TET and vitamin, nucleotide, and amino acid metabolism pathways were the most vulnerable metabolic pathways at dietary exposure level. For key metabolite short chain fatty acids, TET significantly induced the synthesis of butyrate in B. fragilis, rather than C. sporogenes and E. coli. Furthermore, TET induced the release of lipopolysaccharides (LPS) in E. coli and enhanced the immune response; however, there was no obvious effect on B. fragilis. Interestingly, the overall immune response modulation with TET exposure relied on the ratio between E. coli and B. fragilis, possibly due to the neutralization of active LPS from E. coli by the LPS from B. fragilis. Overall, our results showed that the effect of TET from environmental exposure on the host health would be highly dependent on the GM composition, especially for the gut bacterial metabolome and secretome induced immune response.
Introduction
The human gastrointestinal (GI) tract, especially the colon, is colonized with a diverse community of trillions of bacteria, and is considered to be an essential organ with strong interactions with its host, including nutrient synthesis and metabolism, epithelial development, and regulation of immune system responses (Bäckhed et al., 2005; Eckburg et al., 2010; Magnúsdóttir et al., 2015; Morowitz et al., 2011) . More importantly, the gut microbiome (GM)-produced/transformed metabolites such as trimethylamine N-oxide (TMAO), secondary bile acids, branched chain amino acids (BCAAs), and short chain fatty acids (SCFAs) are known to have a direct impact on the host health and diseases (Mcgarr et al., 2005; Pedersen et al., 2016; Wang et al., 2011; Zhang and Davies, 2016) . Also, the GI tract is known as the primary site that facilitates the host immune system-GM interactions, especially through immunoregulatory compounds, such as lipopolysaccharide (LPS) excreted from bacteria (Raetz and Whitfield, 2002; Round and Mazmanian, 2009; Wikoff et al., 2009; Yoo and Lee, 2016) .
As we know, the host's life style and metabolism shape the community composition and functionality of gut flora (Li et al., 2008; Schmidt et al., 2018) . In particular, human ingestion of a multitude of small molecules that are foreign to the body, including environmental chemicals and pharmaceuticals, can directly alter the composition and functionality of indigenous GM-inducing genes responsible for drug metabolism, drug resistance, and stress response (Maier et al., 2018; Maurice et al., 2013; Zhang et al., 2018) . Among them, antibiotics have a major influence on GM, which can disrupt the GM composition and alter its metabolism (Cho et al., 2012; Dethlefsen and Relman, 2011; Hernández et al., 2013) .
Tetracycline (TET) is an extensively used antibiotic for human therapeutic purposes and in veterinary medicine, where its sales represent the largest volume of domestic sales in the U.S., accounting for 70% of all antibiotics (Food and Drug Administration, 2017) . The estimated bioavailability of TET is approximately 77%-88%, and a high level of residue was found in human feces (Agwuh and MacGowan, 2006; Mcvay Jr, 1952) . Up to 242 μg/kg of TET was reported in poultry and dairy products, while up to 20 ng/L and 158 μg/L were reported in surface water and waste water; respectively (Aalipour et al., 2015; Arikan et al., 2008; Borghi and Palma, 2014; Bu et al., 2013; Cháfer-Pericás et al., 2011; Deng et al., 2018; Gulkowska et al., 2008; Javid et al., 2016; Kolpin et al., 2002; Tong et al., 2014) . Thus, there are multiple possible ways of exposing the human GI tract to TET.
While a growing body of evidence suggests the disruption of human microbiota by therapeutic levels of TET (Jung et al., 2018; Roca-Saavedra et al., 2018) , those studies only reported the altered community composition and emergence of TET resistance. Those previous studies mostly focused on the pharmaceutical levels and the effect of low dose exposure (i.e., sub-therapeutic levels and dietary exposure) on TET on GM remains unknown. More importantly, very limited information is available on the effect of TET on the GM metabolome and secretome associated immune response, which are two key functions of the GM, although several studies have shown the effect of TET and TET family antibiotics on the bacterial metabolome, focusing mainly on the approach of understanding their mechanism of action through metabolomics (Hoerr et al., 2016; Jones-Dias et al., 2017; Lin et al., 2014) .
Overall, due to the high complexity of the GM composition, there is no indicator on how the metabolome changes in the ecosystem can be reflected in pure strains. It is of great scientific value to investigate the response of the primary strains to the TET exposure and enable the possible system-wide metabolome prediction based on the community structure. Further, the induced LPS release in E. coli with TET exposure has been reported, while TET itself has the ability to inhibit host immune responses (Bellahsene and Forsgren, 1985; Bostanci et al., 2011; Evans and Pollack, 1993; Sun et al., 2015) . However, the influence of TET on the LPS production from other primary gut bacteria or their mixture, and thereby the effects on the host, remains unclear.
In this study, we selected three model gut bacteria, including Bacteriodes fragilis, Clostridium sporogenes, and Escherichia coli, which represent several types of the most abundant bacterial genera in the gut (Eckburg et al., 2010; Zhang et al., 2018) . Subsequently, a global and targeted metabolomics approach was used to characterize the metabolomic disruption from low dose of TET exposure and to study the possible interactions between LPS subtypes by using high-throughput immune bioassays. In addition, we also used additional experiment to examine and predict the host effect of TET on different GM compositions.
Materials and methods

Bacterial strains and cultivation
Three model bacteria were applied in this study, including Bacteroides fragilis ATCC25285, Clostridium sporogenes ATCC15579, and Escherichia coli K12-MG1655. The rationale was fully described in our previous study . The bacterial cultures were stored at -80°C in a reinforced clostridial medium (RCM) (Oxide, Thermo Scientific Microbiology, Singapore), containing 25% glycerol. All bacteria were revived in RCM in an anaerobic growth incubator at 37°C overnight before the following experiment.
TET treatment of model bacteria
TET hydrochloride was purchased from Sigma-Aldrich, Singapore. The inhibition of TET on model bacteria were tested by dose-response assay, and the growth was monitored by reading the optical density at 600 nm with a spectrophotometer (DR1900, HACH, Southeast Asia). The fitting of the four-parameter logistic curve is used to predict the inhibitory concentration (IC) (Huang et al., 2012) . The detailed methods are mentioned in the supplementary material Text S1.
For the metabolomics and immunological study, each model bacterium was treated with TET at three different dose concentrations (Table S1 ). Sub-pharmaceutical levels of IC 90 and IC 50 for each bacterium was selected as the high and middle dose levels of TET; respectively. The human relevant dietary exposure concentration of TET in the gut was roughly predicted with a previously used model . As a result, the low dose at 0.01 mg/L was selected to simulate the TET concentrations occurring in the gut via the consumption of poultry and dairy products containing TET residues (Aalipour et al., 2015; Cháfer-Pericás et al., 2011) .
The bacterial cultivation and TET treatment followed our previous study . Briefly, 1% (v/v) of overnight revived bacterial culture was inoculated and allowed to grow to the late exponential phase before the TET treatment. All bacterial cultures and controls were prepared in triplicates and were cultivated in an incubating shaker, under anaerobic conditions at 37°C, for 24 h. After incubation, the cell pellets and the secretome were separated via centrifugation at 8000 rpm for 3 min, for metabolomics and immunological studies; respectively. The cell pellets were then rapidly washed in icecooled phosphate buffered saline (PBS) to remove the growth medium residues. Thereafter, the cell pellets immediately proceeded to metabolite extraction, and secretome was stored at −40°C until analysis. Optical density measurements were also conducted upon harvest for normalization.
Metabolite extraction, profiling and QA/QC
The metabolite extraction and profiling was conducted according to our previous study . Briefly, the metabolites were extracted from cell pellets via a pre-chilled extraction buffer (acetonitrile/methanol/water, 2/2/1, v/v/v) by glass bead assisted homogenization and freeze-thaw cycles. The extract was dried by speed-vacuum evaporation (CentriVap Benchtop Centrifugal Vacuum Concentrator, Labconco, U.S.A.) at 10°C, which was followed by reconstitution in acetonitrile/water (1/1, v/v) with a normalized volume by the bacteria culture optical density.
The profiling of metabolites was conducted using a high performance liquid chromatography (HPLC) system (Agilent Technologies) coupled to a 6550 Q-TOF (Agilent Technologies, Singapore), in accordance with our previous study . The metabolite profiling and quality control was detailed in Text S1. Pooled mixture of treated and control samples of each bacteria was run with data-dependent acquisition (DDA) auto-MS/MS and targeted MS/MS of selected precursors .
Metabolites identification and metabolic pathway analysis
The metabolome data processing was carried out using an XCMS online web platform (http://xcmsonline.scripps.edu) (detailed in Text S1). First screening was based on the significant features, with pvalue ≤ 0.05, |fold change| > 1.5, and intensity > 10,000 ion counts. All those features were manually checked to minimize the false positive hits. MS/MS fragment, accurate mass, and in-house retention time match were the methods used for metabolite identification. Open source platforms KEGG (http://www.genome.jp/kegg/) and Metaboanalyst (http://www.metaboanalyst.ca) were incorporated for further pathway analysis. Statistical analysis, including principal component analysis (PCA) and heatmap analysis, was conducted by PAST (https://folk.uio.no/ohammer/past/) and R software (http:// www.R-project.org); respectively.
Derivatization and GC-MS analysis of SCFA
The analysis method of SCFA was modified from a previous study (He et al., 2018) . Briefly, the bacterial extract was derivatized with 2,3,4,5,6-penta-fluorobenzyl bromide (PFBBr) purchased from Sigma-Aldrich, Singapore, prior to gas chromatography-mass spectrometry (GC-MS) analysis. The internal standard 13 C-sodium acetate was purchased from Cambridge Isotope Laboratories. Briefly, 100 mM PFBBr in acetone, 0.5 M phosphate buffer (pH 7), and sample were mixed at a ratio of 14:2:5 (v/v/v) with the spiked internal standard in a glass tube, vortexed, and incubated in a water bath at 60°C for 1.5 h. The derivatized products were then extracted with hexane, followed by drying, reconstituting in toluene, and analyzed using GC system (Agilent technologies), coupled with 5977A mass selective detector (MSD). The detailed GC method is mentioned in Text S1.
Determination of LPS
LPS concentration was determined in the TET treated/control bacterial secretome. Briefly, LPS-free tubes and vials were utilized as well as non-pyrogenic filters. The samples were kept on ice, diluted in pyrogen-free water plus 0.05% Tween 20 (Sigma-Aldrich Singapore), centrifuged at 2500 g for 10 min, and the secretome was frozen at −20°C, pending analysis. Analyses of LPS were performed with a limulus amebocyte lysate (LAL) assay (Charles River, UK) according to the kit instructions (Townsend et al., 2007) . The kit reagents enzymatically reacted with LPS, and subsequently resulted with a color change, which can be measured spectrophotometrically.
Human cell immune stimulation assays
THP-1 cells (ATCC TIB-202) were cultured with RPMI1640 supplemented with 10% FBS and 2 mM L-glutamine under a humidified 5% CO 2 atmosphere at 37°C in incubator. The THP-1 monocytes were maturated by exposure to THP-1 cells in 100 ng/mL phorbol 12-myristate 13-acetate (PMA) for 48 h. After maturation, THP-1 macrophages were cultured with the normal medium for further analysis. The THP-1derived macrophages were then exposed to TET treated/control bacterial secretome for 24 h. A blank control group and a vehicle control group (0.1% DMSO in a culture medium) were prepared in parallel with these experiments. Further 100 ng/mL LPS was used as the positive control and 100 μg/mL polymyxin B (PMB) was used to dissociate the LPS which used as the negative control for the samples with highest LPS concentration. The concentrations of tumor necrosis factor (TNF)alpha, interleukin (IL)-6, and (IL)-1β in culture supernatants were determined using ELISA kits from Wuhan Biotech Co, Ltd., PR China.
QA/QC and statistical analysis
The bacterial metabolome experiment was conducted twice and the relative standard deviation (RSD) was < 15% from replicates in intra and inter-batches. For the in vitro cytokine assays, all data are representative of three or more independent experiments and are presented as the mean (and SD) of triplicate assessments. Differences between groups or treatments were examined for statistical significance using Student's t-test or a one-factor analysis of variance (ANOVA), with Duncan's post-hoc test, with significance level set at *p < 0.05, and **p < 0.01.
Results and discussion
Bacterial growth under low dose TET exposure
We first evaluated the susceptibility of three model bacteria, B. fragilis, C. sporogenes, and E. coli to TET. The growth of the model bacteria under different dose levels of TET is shown in Fig. S1 . B. fragilis, and C. sporogenes showed lower IC 90 (0.16 and 0.13 mg/L; respectively) compared to that of E. coli (7.4 mg/L). The possible dietary level exposure concentration of the GM to TET was approximately 0.015 mg/L (Text S1), which can induce subtle effects on the growth of B. fragilis, where its IC 10 was 0.008 mg/L. Accordingly, to investigate the effect of low dose TET exposure on the metabolome and the immune response, we selected sub-pharmaceutical level of IC 90 and IC 50 for each strain as the high and middle levels of exposure, respectively, and 0.01 mg/L as the low exposure concentration of the possible dietary level of exposure.
Global profiling of the metabolome
We profiled the global metabolome of three model bacteria to observe their response to three different doses of TET. In general, higher levels of TET induced more responsive metabolite features in each bacterium. For instance, significantly dysregulated features observed in B. fragilis under high and middle doses of TET exposure were 5.5 and 4.4 times higher than that in the low; respectively ( Figs. 1a and S2) . However, the responsive feature numbers were highly varying among the three bacteria under the high dose of TET, which was 16.5%, 3.2%, and 5.5% of the total detected feature numbers for B. fragilis, C. sporogenes, and E. coli, respectively, where B. fragilis showed comparatively higher sensitivity towards TET.
To get further comparison on metabolic responses of the three model bacteria to TET, we have conducted meta-analysis of the responsive features at the high dose. In general, most of the features were not shared across the three model organisms. Only 36 significantly dysregulated features were found to be shared among three model bacterial strains, which was < 5% of the total significant features in each bacterium, while this pattern was consistent among all dose levels ( Figs. 1b and S3 ). Further principle component analysis of responsive features among three model bacteria showed a separation among three bacteria (Fig. 1c ). Collectively, our results suggest the species-specific and concentration-dependent metabolic response of model gut bacteria to TET.
The above findings revealed a difference in sensitivities of the metabolome of each bacterium towards TET, although the IC 90 was quite similar for B. fragilis and C. sporogenes. The response of metabolite features may non-growth associated, as we dosed TET at the late exponential phase. The target sites, resistance capabilities, and uptake mechanisms specific to a bacterium may lead to the difference in their responses towards the same antibiotic. For instance, TET exposure can inhibit the cell wall synthesis of E. coli (Cheng and Snell, 1961) ; but not, however, in Staphylococcus aureus (Hash et al., 1964) . Moreover, B. fragilis and E. coli has shown efficient uptake of TET through outer membrane porin channels (Fayolle et al., 1980; McMurry and Levy, 1978; Schnappinger and Hillen, 1996) , Higher and fast enrichment of Bacteroides compared to Firmicutes in the gut microbial community treated with TET further reveals that the genera Bacteroides are more competitive under TET exposure (Jung et al., 2018) .
Metabolite identification and dose-response relationship
Metabolite identification
We further identify the significantly dysregulated features in model bacteria treated with the high dose of TET by MS/MS data and retention time matching. A total of 116 metabolites were identified across three model bacteria, and 98 of them were significantly dysregulated in at least one bacterium (Table S2 ). The responsive metabolites across different model bacteria were compared, as shown by the heatmap analysis in Fig. 2 . The majority of the metabolites in B. fragilis were upregulated at the high level of TET exposure, which contrasted with that in C. sporogenes and E. coli, where more features were down-regulated. The two Gram negative bacteria, B. fragilis and E. coli showed more shared features among them in meta-analysis; however, they did not show a close relationship according to the hierarchical clustering of identified metabolites.
Dose-response relationship of responsive metabolites
To understand the response of metabolites under different doses of TET, we searched the identified metabolites against the middle and low dose levels of TET. Most of these metabolites were not significantly dysregulated under the low and middle levels of exposure. For example, among the 60 significantly dysregulated metabolites in B. fragilis under the high level of TET, only 38 and 20 were found to have significant dysregulation under middle and low levels of TET; respectively (Table  S2 ). Further, part of the identified metabolites showed a dose-response relationship (Fig. 3) . For instance, the fold change of serine is in B. fragilis exposed to high, middle and low levels of TET were 2.1 ± 0.2, 1.2 ± 0.2 and 1.1 ± 0.3; respectively ( Fig. 3a and Table S2 ).
The higher fold change in the high dose may due to the higher availability of TET to act on the target sites; however, the low dose still can induce alterations in some metabolites such as aspartic acid and pyroglutamic acid (Fig. 3a) , which emphasize the possible effect of TET intake on gut microbial metabolism through the consumption of food products containing TET residues. There are a number of other targets of TET, such as fermentation and oxidation process (Hash et al., 1964) , cell wall synthesis (Miller, 1969) , and vitamin metabolism (Hash et al., 1964) , in addition to its primary target of inhibiting the protein synthesis. Therefore, the resulting metabolic changes could be from direct pathway targeting by TET or due to the inhibition of synthesis of proteins involved in these pathways (Hash et al., 1964) . Dysregulations in metabolites related to vitamin metabolism, nucleotide and amino acid biosynthesis have been reported in previous bacterial metabolomics studies, which also include antibiotics with a similar mode of action (Belenky et al., 2015; Zampieri et al., 2017) .
Metabolic pathway analysis
We next performed a pathway impact analysis to examine the pathways highly affected by the TET. In general, the riboflavin (vitamin B2) metabolism was among one of the highly affected pathways in B. fragilis and C. sporogenes while nucleotides (i.e., purine and pyrimidine), amino acids (i.e., alanine, aspartate, and glutamate), and the butanoate metabolism were significantly affected in B. fragilis and E. coli under the exposure to the high dose of TET (Figs. 4, S4, and S5) . Further, the nucleotide, amino acid, vitamin, and fatty acid metabolism are among the significantly affected pathways under the low dose of TET (Fig. S5) . 
Effect of TET on vitamin metabolism
Vitamin synthesis and metabolism were highly affected under TET exposure, as reflected in the global pathway analysis and metabolite identification. For instance, metabolites involved in the riboflavin metabolism, such as riboflavin and D-ribose 5-phosphate, were significantly dysregulated in B. fragilis in 1.6 ± 0.2 and 3.1 ± 0.9 folds; respectively at the high level of TET exposure (Fig. S6) ; while other vitamin B related metabolites, such as 4-Pyridoxic acid, were significantly dysregulated, even at the middle level of exposure (Fig. 3 , Table S1 ). The genera to which the three model bacteria belong are known vitamin producers in the GM, while certain B vitamins were among the key metabolites supplied to the host by gut bacteria (Magnúsdóttir et al., 2015; Morowitz et al., 2011) . In addition, vitamin B is also known as a biomarker linked to adult brain volume (Hooshmand et al., 2016) . Thus, the effect on the vitamin metabolism by TET may affect the host metabolic requirements and health conditions.
Effect of TET on lipid and fatty acid metabolism
Metabolites related to lipids and fatty acid metabolism in B. fragilis and C. sporogenes were affected under TET exposure, with a fold change ranging from 0.07 to 2.7 and 0.4 to 1.2; respectively, under high dose of TET exposure (Figs. 2, 3, and Table S2 ). Interestingly, metabolites, such as linoleic acid in B. fragilis, showed a dose-response relationship to TET (Fig. 4) while some glycerophospholipids and ceramides were significantly changed in B. fragilis, even at the low dose of TET exposure ( Fig. 3 and Table S2 ). A high effect on plasma lipid metabolites of mice treated with TET has been observed, which may be mediated through the effect of TET on the GM (Behr et al., 2017) . Further, linoleic acid related, GM produced metabolites, such as conjugated linoleic acids (CLA), are known to be involved in body weight gain, cardiovascular disease, insulin resistance, and lipid peroxidation, which further emphasized the possible metabolically driven effects of TET on host health (Devillard et al., 2007; Mensink, 2005; Risérus et al., 2004) .
Effect of TET on SCFAs
We incorporated a GC-MS based approach to analyze the SCFAs, which cannot be detected in our global metabolomic method. The SCFA production in B. fragilis showed a higher sensitivity to TET exposure (Fig. 3b) , with a significantly high fold change of propionic, butyric, and valeric acid from 2 to 9.2 to the control, at the high dose of TET exposure. However, this was not observed on other two bacteria. The increased cecal SCFA levels, with an increase in percentage body fat were previously reported under the exposure of TET family antibiotics (Cho et al., 2012) . The SCFA has been the focus of GM studies in the past, and the increased SCFA have been shown to have connections to obesity and numerous other metabolic diseases (Turnbaugh et al., 2006; Zhang and Davies, 2016) . Collectively, our results and the literature suggest that the TET-induced alteration in gut microbial SCFA metabolism, and thereby can induce adverse effects on the host's health. The sensitivity difference among the three primary bacteria suggested that the overall effect of TET in the GM will be highly dependent on the GM composition.
Immunogenicity of LPS subtypes under TET exposure
Knowing some antibiotics such as ampicillin and ciprofloxacin at the therapeutic level can probably increase the releasing of LPS (Prins et al., 1994) , we first determined the impact of TET on the LPS concentration in the secretome of Gram negative bacteria (i.e., B. fragilis and E. coli), which is known to elicit a strong immune response in mammalian cells (Raetz and Whitfield, 2002; Vatanen et al., 2016; Yoo and Lee, 2016) , As shown in (Fig. 5a) , the LPS concentration measured by LAL assay was significantly higher in the E. coli treated with TET, with a fold change of 1.8, 1.6, and 1.2 for high, medium and low dose exposure. In contrast, B. fragilis did show a slightly decreasing trend, with increasing TET levels.
We further confirmed the secretome-induced immune response by the inflammatory cytokine production of THP-1 macrophages cells dosed with the bacterial secretome. Generally, the cytokine (i.e. (TNF)alpha, (IL)-6, and (IL)-1β) release with E. coli secretome was comparatively higher to that in B. fragilis (Fig. 5b) . A clear dose-response relationship with TET was observed for E. coli, where there was a lack of or slight increase with the B. fragilis secretome. Besides LPS, many other gut microbiota-derived metabolites, such as SCFAs and indoles, have been reported to modulate the immune response (Corrêa-Oliveira et al., 2016; Gao et al., 2018) , To estimate the contribution of LPS in the cytokine production, we applied PMB to dissociate the LPS, and observed a significant reduction of cytokine production in PMB treated E. coli secretome at the high level of TET, suggesting the primary involvement of E. coli LPS on the immune response modulation (Fig. 5b) .
Due to the difference in the effects of TET on B. fragilis and E. coli LPS activity, we were interested in observing the LPS activity in a bacteria mixture. Furthermore, a recent study reported the inhibition of immune response induced by E. coli by the LPS of Bacteroides species (Vatanen et al., 2016) . Thus, we further expanded our study to observe the combined effect of the secretome of two bacteria under TET exposure. Generally, the dosing of increasing amount of B. fragilis secretome to the constant volume of E. coli secretome inhibited the total LPS activity in the mixture, regardless of the TET level (Fig. 5c ), reconfirming the neutralization effect of B. fragilis derived LPS on E. coli derived LPS. More interestingly, we have observed the effect of TET on the increase of LPS activity was highly dependent on the ratio of B. fragilis to E. coli LPS. For instance, at 0.01:1 to 1:1 ratios of B. fragilis:E. coli LPS, the fold change of LPS activity compared to control under the high TET exposure is in the range of 1.6-1.9, while the fold change was reduced to 1.3 at 10:1 ratio of B. fragilis:E. coli LPS. At the low exposure level of TET, the LPS activity change was even lower than 1 (i.e., 0.6) when B. fragilis was dominant (ratio: 10:1). Collectively, our results imply that the total LPS activity and the immune dysregulations caused in response to TET is highly dependent on the B. fragilis:E. coli ratio and thereby can vary upon the individual, according to their GM composition (Fig. 5d) . A few previous studies have suggested that the immune response has relied on the ratio between Bacteroidetes-to-E. coli LPS (d' Hennezel et al., 2017; Vatanen et al., 2016) . Furthermore, the production of antagonistic form of lipopolysaccharide (LPS) Bacteroides dorei has been reported in a recent study, however the mechanism is yet to be explored (Vatanen et al., 2016) . The ratio of B. fragilis:E. coli in the gut can greatly vary between individuals, based on a number of other reasons, such as diet, age, disease, and geological locations. For instance, the relative abundance of E. coli is low compared to that of B. fragilis in the GM of Russian infants, while the relative abundance of B. fragilis increased over E. coli with age. In contrast, the relative abundance of B. fragilis is higher than E. coli in Finnish and Estonian infants, without significant temporal variation (Vatanen et al., 2016) . Thus we can expect a personalized response from the host immune system to the GM exposure of TET.
Conclusions
In conclusion, our metabolome study of the three model bacteria showed species-specific, concentration-dependent response of bacteria towards non-therapeutic levels of TET exposure with dysregulations in several metabolic pathways, known to be related with several host diseases, such as weight gain and diabetes. More importantly, the dysregulation of nucleotide, amino acid, vitamin, and fatty acid metabolism at dietary dose emphasizes the risk of facing alterations in the GM of non-antibiotic users. The result of immune response and LPS activity revealed that the TET could have a great impact on GM LPS production and modulate the host immune response. Interestingly, the impact of TET was observed to be highly bacteria-dependent and varied with the ratio of B. fragilis:E. coli, which can be different for each individual. Therefore, it is likely that the risk of TET exposure from either sub-pharmaceutical or dietary exposure depends on the gut bacterial composition, leading to a "personalized" response of TET to the metabolome and immune regulations of the host. The interaction between chemical, bacteria and effect on the host is very complex, and future study is warranted. The chemical can affect the ratio of bacteria, and the later will pre-or post-determine the effect of the former on the possible effect on the host.
